Optimer Pharmaceuticals Announces Oral Presentation at Digestive Disease Week (DDW) Featuring Data From the Second Fidaxomicin Phase 3 Trial

Thursday, April 22, 2010 General News J E 4

SAN DIEGO, April 22 Optimer Pharmaceuticals, Inc. (Nasdaq: OPTR) announced that data from the second fidaxomicin Phase 3 clinical study will be presented in an oral presentation at Digestive Disease Week (DDW) 2010 in New Orleans.

About Optimer Pharmaceuticals

Optimer Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing innovative anti-infectives to treat serious infections and address unmet medical needs. Optimer has two late-stage anti-infective product candidates under development. Fidaxomicin is a narrow spectrum antibiotic being developed for the treatment of Clostridium difficile infection. Optmer has reported positive top-line results from two Phase 3 trials of fidaxomicin. Pruvel(TM) is a prodrug in the fluoroquinolone class of antibiotics being developed as a treatment for infectious diarrhea. Optimer has also successfully completed two Phase 3 trials with Pruvel. Additional information can be found at


"Randomized Clinical Trial (RCT) in Clostridium difficile Infection (CDI) Confirms Superiority of Fidaxomicin over Vancomycin" Oral Presentation by: Stuart Johnson, M.D. Tuesday, May 4, 2010 2:15pm-3:45pm Central Daylight Time Abstract number: 828630 Location: Ballroom C, Ernest N. Morial Convention Center

SOURCE Optimer Pharmaceuticals, Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Cardica to Announce Fiscal 2010 Third Quarter Fina...
First Coast Service Options Opens New Office in Co...